Ultrasound-activated copper-based sonosensitizer for dual-amplified ROS-mediated tumor therapy and cuproptosis induction

anti-tumor studies showed that the CCG MPN group under US treatment exhibited a better anti-tumor performance. This multimodal approach overcomes the limitations of the tumor microenvironment, offering a synergistic strategy to enhance tumor therapy efficiency through combined ROS generation and cuproptosis activation.